Drug Trial Radar · NCT06454110
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Feb 2028
Primary completion
Dec 2030
Study completion Dec 2031
Sponsor
- Lead sponsor
- NovelMed TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, open-label study designed to To evaluate the safety and efficacy of NM8074 in reducing proteinuria relative to baseline in IgAN patients after 99 days of treatment.
Conditions
- IgA Nephropathy
Interventions
NM8074Drug
NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline or Percent Change from Baseline in urine protein to creatinine concentration ratioTime frame: Up to Study Day 99
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.